

Pipeline

	Program	Indication	Discovery/ Preclinical	Phase 1	Phase 2	Phase 3	Partnerships	Upcoming Milestones
Nykode								
Oncology	VB10.16 (off-the-shelf)	HPV16+ cervical cancer ¹					¹	1H23: Updated data
		HPV16+ head and neck cancer						
	Internal (off-the-shelf)	Undisclosed targets						
Infectious Disease	VB10.CO2	SARS-CoV-2					²	2H22: Interim data
	Internal	Undisclosed targets						
Partnered								
Oncology	VB10.NEO (individualized)	Melanoma, lung, bladder, renal, head and neck					³	
	VB10.NEO (individualized)	Locally advanced and metastatic tumors					³	
	Regeneron (programs 1 – 3) (off-the-shelf)	Undisclosed					⁴	
Infectious Disease	Regeneron (programs 4 – 5)	Undisclosed					⁴	

1. Roche supplies atezolizumab; 2. Collaboration with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine; 3. Genentech has an exclusive license to VB10.NEO; 4. Collaboration with Regeneron